Delcath Systems to Attend BTIG MedTech Conference in Utah
ByAinvest
Tuesday, Jan 27, 2026 8:08 am ET1min read
DCTH--
Delcath Systems, an interventional oncology company, will participate in the BTIG 13th Annual MedTech conference in Utah. The company's proprietary products, HEPZATO KIT and CHEMOSAT, are designed to treat primary and metastatic liver cancers. HEPZATO KIT is a combination drug and device product, while CHEMOSAT is a Class III medical device used in percutaneous hepatic perfusion procedures. The company's products aim to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet